FDA approved drugs as potential Ebola treatments [v2; ref status: indexed, http://f1000r.es/554]

Sean Ekins1, Megan Coffee2

1Collaborations in Chemistry, 5616 Hilltop Needmore Road, Fuquay-Varina, NC, 27526, USA
2Center for Infectious Diseases and Emergency Readiness, University of California at Berkeley, 1918 University Ave, Berkeley, CA, 94704, USA

Abstract

In the search for treatments for the Ebola Virus, multiple screens of FDA drugs have led to the identification of several with promising in vitro activity. These compounds were not originally developed as antivirals and some have been further tested in mouse in vivo models. We put forward the opinion that some of these drugs could be evaluated further and move into the clinic as they are already FDA approved and in many cases readily available. This may be important if there is a further outbreak in future and no other therapeutic is available.

This article is included in the Ebola
As the Ebola outbreak continues and the costs spiral\(^1\) we should perhaps be considering what alternative treatments are close to hand in Africa to complement the public health measures that have been used to date\(^2\). Two independent studies funded by the US Defense Threat Reduction Agency in 2013 identified FDA approved drugs worthy of further evaluation. This work now seems prescient although it appears to have not been followed through to any public conclusion.

In one study, the antimalarials amodiaquine and chloroquine (Figure 1) were found to be active using *in vitro* cell culture assays and an *in vivo* mouse model\(^3\). Both drugs are cheap, generally safe, and likely readily accessible in Africa. These compounds have also shown relatively broad activity against other viruses *in vitro* and *in vivo* in animal models (Dengue, Coronavirus OC43, SARS etc.)\(^4\)–\(^7\). A second study suggested selective estrogen receptor modulators (SERM) clomiphene and toremifene (Figure 1) as inhibitors of Ebola virus\(^8\). The latter compounds are likely more accessible in the west and indicates that other FDA or EMEA approved drugs may be worth testing including those with hormonal effects that are SERMs. More recent work from 2014 in Europe identified a further 3 FDA drugs, amiodarone, dronedarone and verapamil (Figure 1) that inhibit filovirus entry at plasma levels attainable in humans\(^9\). The mechanism of action for most of these drugs is unknown although, using computational methods we have recently shown that the antimalarials and SERMs may share some pharmacophore features which may be important to infer a potential common target or targets\(^10\). To our knowledge likely well over 100 small drug-like molecules have now been identified with activity against the Ebola virus including over 50 FDA drugs derived from a reporter assay at NCATS\(^11\)–\(^15\).

As we await the development of a vaccine or biologic could we consider assessing the efficacy of the antimalarials or the other ‘FDA approved drugs’, as either treatments or prophylactics to prevent the Ebola virus from spreading further? While there can be no guarantee they will work (perhaps requiring adjusted dosage) they may be a last resort. It is possible there are other “non-antiviral” that are widely used in Africa that may also be effective against Ebola. Another example of where ‘non-antiviral’ FDA approved drugs have been found to have ‘anti-viral activity’ is for Hepatitis Virus B and D where the sodium taurocholate co-transporting polypeptide (NTCP) was identified as a receptor\(^16\) and screening produced drugs such as azelastine, pioglitazone, glyburide, irbesartan and ezetimibe that inhibited the transporter and may provide potential treatments\(^17\),\(^18\). Of these compounds, azelastine has been shown to possess *in vitro* activity against Hepatitis Virus B to date\(^18\).

---

**Figure 1.** FDA approved drugs of most interest for repurposing as potential Ebola virus treatments.
The aforementioned screens of FDA approved drugs for Ebola virus activity, were far from comprehensive, covering only some of the known approved drugs currently in use. In an age where drug repurposing is in vogue and it can be facilitated by computational methods, it would seem a valuable resource for finding compounds active against the Ebola virus. For example, the recent pharmacophores developed for Ebola and virtual screens could be used to computationally search larger datasets of FDA approved drugs and prioritize additional compounds for testing in vitro. Even using the known actives (Figure 1) to perform simple similarity searches in a set of over 1300 Approved Drugs in a mobile app (http://molmatinf.com/approveddrugs.html) could prioritize further compounds for testing (Figure S1–Figure S7). For example molecules with structural similarity to chloroquine (Figure S1) not only includes known actives like amodiaquine and hydroxychloroquine but also suggests the antimalarials primaquine, halofantrine and the antihistamine chlorpheniramine. Molecules with similarity to amodiaquine include the kinase inhibitors neratinib and gefitinib while other kinase inhibitors have been suggested as having activity against Ebola virus, these may not be readily accessible in Africa. Other compounds retrieved by similarity include the antimicrobial pentamidine (Figure S3, Figure S4, Figure S7), the antiemetic trimethobenzamide (Figure S3–Figure S7) and the antihistamine doxylamine (Figure S5). Certainly more sophisticated and exhaustive searches than this could be tried. Deciding which molecules to use or test should also involve the physician’s perspective. Alternative treatments may also be found by studying those close to patients who may not have contracted the disease and are taking a drug for another chronic disease. Whether we can find a treatment for Ebola by serendipity is questionable but some of the published studies with known drugs might point us in the right direction of where to look. The opportunity to put already available drugs like those already identified back on the table may be a useful tool for frontline doctors to have and is worthy of more urgent discussion and research.

Author contributions
Both authors contributed to the writing of the manuscript.

Competing interests
Neither author has competing interests.

Grant information
The author(s) declared that no grants were involved in supporting this work.

Acknowledgments
Dr. Christopher D. Southan, Dr. Joel S. Freundlich, Dr. Peter Madrid and Dr. Nadia Litterman are acknowledged for discussions on Ebola.

Supplementary Figures

Supplemental Figure 1. Chloroquine similarity in Approved Drugs mobile app http://molmatinf.com/approveddrugs.html.

Supplemental Figure 2. Amodiaquine similarity in Approved drugs mobile app http://molmatinf.com/approveddrugs.html.
Supplemental Figure 3. Clomiphene similarity in Approved drugs mobile app http://molmatinf.com/approveddrugs.html.

Supplemental Figure 4. Toremifene similarity in Approved drugs mobile app http://molmatinf.com/approveddrugs.html.

Supplemental Figure 5. Verapamil similarity in Approved drugs mobile app http://molmatinf.com/approveddrugs.html.

Supplemental Figure 6. Amiodarone similarity in Approved drugs mobile app http://molmatinf.com/approveddrugs.html.
Supplemental Figure 7. Dronedarone similarity in Approved drugs mobile app http://molmatinf.com/approveddrugs.html.

References

1. Butler D, Morello L: Ebola by the numbers: The size, spread and cost of an outbreak. Nature. 2014; 514(7522): 284–5. PubMed Abstract | Publisher Full Text

2. Trad MA, Fisher DA, Tambyah PA, et al.: Ebola in west Africa. Lancet Infect Dis. 2014; 14(11): 1045. PubMed Abstract | Publisher Full Text

3. Madrid PB, Chopra S, Manger ID, et al.: A systematic screen of FDA-approved drugs for inhibitors of biological threat agents. PLoS One. 2013; 8(4): e60579. PubMed Abstract | Publisher Full Text | Free Full Text

4. de Wilde AH, Jochmans D, Posthuma CC, et al.: Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother. 2014; 58(8): 4875–84. PubMed Abstract | Publisher Full Text | Free Full Text

5. Keyaerts E, Li S, Vijgen L, et al.: Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. Antimicrob Agents Chemother. 2009; 53(8): 3416–21. PubMed Abstract | Publisher Full Text | Free Full Text

6. Vincent MJ, Bergeron E, Benjannet S, et al.: Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virology. 2005; 328: 69. PubMed Abstract | Publisher Full Text | Free Full Text

7. Boonyasuppayakorn S, Reichert ED, Manzano M, et al.: Amodiaquine, an antimalarial drug, inhibits dengue virus type 2 replication and infectivity. Antiviral Res. 2014; 106: 125–34. PubMed Abstract | Publisher Full Text | Free Full Text

8. Johansen LM, Bramann JM, Delos SE, et al.: FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci Transl Med. 2013; 5(190): 190ra79. PubMed Abstract | Publisher Full Text | Free Full Text

9. Gehring G, Rohrmann K, Atencion N, et al.: The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry. J Antimicrob Chemother. 2014; 69(8): 2123–31. PubMed Abstract | Publisher Full Text

10. Ekins S, Freundlich JS, Coffee M, et al.: A common feature pharmacophore for FDA-approved drugs inhibiting the Ebola virus [v2; ref status: indexed, http://f1000r.es/4w8t]. F1000Res. 2014; 3: 277. PubMed Abstract | Publisher Full Text | Free Full Text

11. Veljkovic V, Loiseau PM, Figadere B, et al.: Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOVLA virus infection [v2; ref status: indexed, http://f1000r.es/53d7]. F1000Res. 2015; 4: 34. Publisher Full Text

12. Kouznetsova J, Sun W, Martinez-Romero C, et al.: Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs. Emerg Microbes Infect. 2014; 3: e84. Publisher Full Text

13. Long J, Wright E, Molesti E, et al.: Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry [v2; ref status: awaiting peer review, http://f1000r.es/52g3]. F1000Res. 2015; 4: 38. Publisher Full Text

14. Litterman N, Lipinski C, Ekins S, et al.: Small molecules with antiviral activity against the Ebola virus [v1; ref status: indexed, http://f1000r.es/5233]. F1000Res. 2015; 4: 28. Publisher Full Text

15. Picazo E, Giordanetto F: Small molecule inhibitors of ebola virus infection. Drug Discov Today. 2015; 20(2): 277–286. PubMed Abstract | Publisher Full Text

16. Yan H, Zhong G, Xu G, et al.: Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife. 2012; 1:
17. Dong Z, Ekins S, Polli JE, et al. Quantitative NTCP pharmacophore and lack of association between DILI and NTCP Inhibition. *Eur J Pharm Sci.* 2014; 66C: 1–9. PubMed Abstract | Publisher Full Text

18. Fu LL, Liu J, Chen Y, et al. In silico analysis and experimental validation of azelastine hydrochloride (N4) targeting sodium taurocholate co-transporting polypeptide (NTCP) in HBV therapy. *Cell Prolif.* 2014; 47(4): 326–35. PubMed Abstract | Publisher Full Text

19. Blatt J, Farag S, Corey SJ, et al. Expanding the scope of drug repurposing in pediatrics: the Children’s Pharmacy Collaborative. *Drug Discov Today.* 2014; 19(11): 1696–1698. PubMed Abstract | Publisher Full Text

20. Dyall J, Coleman CM, Hart BJ, et al. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. *Antimicrob Agents Chemother.* 2014; 58(8): 4885–93. PubMed Abstract | Publisher Full Text | Free Full Text

21. Huang R, Southall N, Wang Y, et al. The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. *Sci Transl Med.* 2011; 3(80): 80ps16. PubMed Abstract | Publisher Full Text | Free Full Text

22. Oprea TI, Mestres J. Drug repurposing: far beyond new targets for old drugs. *AAPS J.* 2012; 14(4): 759–63. PubMed Abstract | Publisher Full Text | Free Full Text

23. Walsh CT, Fischbach MA. Repurposing libraries of eukaryotic protein kinase inhibitors for antibiotic discovery. *Proc Natl Acad Sci U S A.* 2009; 106(6): 1682–86. PubMed Abstract | Publisher Full Text | Free Full Text

24. Dudley JT, Deshpande T, Butte AJ. Exploiting drug-disease relationships for computational drug reprioritization. *Brief Bioinform.* 2011; 12(4): 303–11. PubMed Abstract | Publisher Full Text | Free Full Text

25. Dudley JT, Sirota M, Shenoy M, et al. Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. *Sci Transl Med.* 2011; 3(96): 96ra76. PubMed Abstract | Publisher Full Text | Free Full Text

26. Ekins S, Williams AJ, Krasowski MD, et al. In silico repositioning of approved drugs for rare and neglected diseases. *Drug Discov Today.* 2011; 16(7–8): 296–310. PubMed Abstract | Publisher Full Text

27. Ekins S, Southan C, Coffee M. Finding small molecules for the ‘next Ebola’ [v1; ref status: awaiting peer review, http://f1000res.es/542]. *F1000Res.* 2015; 4: 58. Publisher Full Text
Open Peer Review

Current Referee Status:  

Version 2

Referee Report 11 March 2015

doi:10.5256/f1000research.6664.r7908

James Popp
Stratoxon LLC, Lancaster, PA, USA

Additions included in the revised version have improved the submission.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Competing Interests: No competing interests were disclosed.

Version 1

Referee Report 27 February 2015

doi:10.5256/f1000research.6608.r7744

James Popp
Stratoxon LLC, Lancaster, PA, USA

This Opinion Article provides an interesting and potentially important view that currently approved drugs may have activity against the Ebola virus that would allow rapid entry into clinical use due to the previous approved status. While this concept is consistent with previous scientific discussions of the potential for “repurposing” of drugs, the focus on the Ebola virus is very germane to the immediate medical crisis and the need for effective therapies related to Ebola infections. The presented opinion provides a high level overview of previously published data identifying agents with potential efficacy and the opinion appropriately expands the concept to using computational approaches to identify other drugs with potential activity. The concept of studying Ebola virus exposed individuals who did not contract the disease as an approach to identify drugs that may have a beneficial effect is very good although fraught with difficulties when such studies may be attempted under “field” conditions. This point should be expanded.

The authors are encouraged to give additional thought and provide additional opinion regarding the approach(s) that can or should be taken beyond the identification of drugs that may have potential efficacy in an Ebola outbreak. Since the opinion recommends additional screening of drugs for potential efficacy, how will (should) decisions be made to select specific agents for further evaluation or clinical
use? What criteria should be deemed essential to make decisions in a selection process? These are critical issues since limited resources (and they will always be limited) will require decisions as to which molecules will be prioritized in the selection for the next level of evaluation or use.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

**Competing Interests:** No competing interests were disclosed.

---

Author Response 02 Mar 2015

Sean Ekins, Collaborations in Chemistry, USA

Thank you for your review. In the latest version, the compounds from figure 1 with known ebola virus activity in vitro and in vivo, were used as a starting point for similarity searching >1300 FDA approved drugs in a mobile app (the same type of approach could likely be taken with other software). This would suggest several FDA approved molecules that could be readily tested and may be accessible in Africa (e.g. additional antimalarials and antimicrobials etc). While its unclear if these have been tested to date this type of approach could be taken on a larger scale. It may also point to the importance of a tertiary amine in these compounds for their mechanism.

In our most recent opinion http://f1000research.com/articles/4-58/v1 we discuss using the physician's perspective to group treatments which addresses the reviewers question of what criteria may be essential.

**Competing Interests:** None

---

Referee Report 23 February 2015

doi:10.5256/f1000research.6608.r7764

Raymond Lin

Communicable Diseases Division, National Public Health Laboratory, Ministry of Health, Singapore, Singapore

This is a different take on the approach to therapeutics for Ebola. The idea of using non-antivirals as potential therapeutics has been broached before, and it is natural to extend that proposition to Ebola. The authors provide a good summary of some candidate agents and the laboratory evidence to suggest it might be worth a try. Although the mechanistic explanation is not available, one mechanism which is common to some of them is by their effect on cell membrane transport through pores. The use of this class of drugs would also largely overcome some ethical issues which pertain to experimental drugs. Of course, in practice, the conduct of clinical trials would be more challenging than might appear. The finding of appropriate cases and controls, and the fact that mortality seems also largely determined by early access to supportive measures like re-hydration- these will complicate the ability to detect an outcome difference. On the subject of re-repurposing of drugs, we note also that some non-Ebola antivirals might be re-purposed for Ebola e.g. favipiravir, which has been approved for influenza in some countries.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

**Competing Interests:** No competing interests were disclosed.

Author Response 02 Mar 2015

**Sean Ekins, Collaborations in Chemistry, USA**

Thank you for your review and comments. We also mention favipiravir and other non-Ebola antivirals in our recent review http://f1000research.com/articles/4-38/v1.

**Competing Interests:** None